State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs 10X Genomics Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.3× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days and 10X Genomics Inc for 91 Days on average.
| SJNK | TXG | |
|---|---|---|
Market Cap | $4.35B | $10.07B |
Volume | 3,211,044 | 5,657,286 |
Sector | Fixed Income | Health |
52-Week High | $25.57 | $97.74 |
52-Week Low | $24.13 | $11.48 |
Typical Hold Time | 41 Days | 91 Days |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.18 with a slight 24-hour decline of 0.08%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF has maintained consistent dividend payments recently, with three distributions of $0.14-$0.15 scheduled for late 2026. Institutional activity shows mixed sentiment with Cetera Investment Advisers and Balefire LLC reducing positions in recent quarters.
The ETF faces headwinds from the current bearish technical setup while offering yield advantages over Treasury securities. Key risks include interest rate sensitivity and high-yield bond market volatility. Investors should weigh the attractive dividend yield against the technical weakness and institutional selling pressure when considering position sizing.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →